Tiffany Thorn
Chief Executive Officer BiVictriX Therapeutics
Experienced ADC executive with a sixteen-year career in healthcare spanning the biotech and clinical setting. Founder of BiVictriX and pioneer of the bsADC approach. Qualified Clinical immunologist, with experience in frontline clinical care. Co-Chair of the UK Sepsis Trust
Seminars
Wednesday 18th March 2026
Conditional Logic-Gated Bispecific ADCs: Harnessing Novel Dual Antigen Fingerprints to Expand Efficacy & Minimize On-Target/Off-Tissue Toxicity
4:00 pm
- Conditional logic-gated bispecific ADCs offer a next-generation strategy for precise tumor targeting and improved efficacy in heterogeneous cancers
- By exploiting unique dual-antigen expression fingerprints, they enable selective payload delivery to malignant cells, enhancing potency while minimizing on-target/off-tissue toxicity
- Highlighting key design principles, preclinical validation, and translational insights demonstrating how logic-gated ADCs can overcome the limitations of conventional ADCs and expand therapeutic opportunities across difficult-to-treat tumors
